Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Research topic
No spam. Unsubscribe anytime.
Research subcommittee urges expanded federal funding, AI investment and national clinical research infrastructure
Summary
Dr. Randy Bateman presented four research recommendations urging Congress and HHS to increase federal research funding, sustain and expand long‑term prevention trials, invest in AI and big data, and build a coordinated national AD/ADRD clinical research infrastructure modeled on the National Cancer Institute system.
Dr. Randy Bateman, chair of the research subcommittee, presented a four‑point set of recommendations urging stronger federal support for Alzheimer’s research and a national infrastructure to accelerate trials and implementation. "Our recommendation number 1 is to ensure research directions are determined by scientific experts using evidence based decision making and input from people living with Alzheimer's disease and related dementias and their caregivers," Bateman said, urging inclusion of people with lived experience in setting priorities.
The subcommittee recommended sustaining current trials and funding new long‑term prevention and early intervention trials, noting trial readouts expected in 2027 and 2028 and arguing that prevention trials could yield larger clinical benefit than treatments started in the symptomatic phase. The group also pressed for congressional and HHS investments in AI and big‑data applications to accelerate discovery, diagnosis and care, and recommended that the revised national plan establish a coordinated national AD/ADRD clinical research infrastructure modeled on the National Cancer Institute system to scale prevention trials and treatment delivery.
